Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial

Reuters
05/13
Madrigal Pharmaceuticals Inc. Publishes Presentation on Compensated MASH Cirrhosis and Rezdiffra Data from Phase 3 MAESTRO-NAFLD-1 Trial

Madrigal Pharmaceuticals Inc. recently presented at EASL 2025, focusing on their leadership in addressing MASH (Metabolic Associated Steatohepatitis) and showcasing new findings on Compensated MASH Cirrhosis (F4c). The presentation included an overview of F4c and clinically significant portal hypertension, alongside a review of new two-year open-label data from the Phase 3 MAESTRO-NAFLD-1 trial. Through these insights, Madrigal aims to reinforce confidence in MAESTRO-NASH outcomes. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on May 13, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10